Women's Lifestyle Balance Study (LB)
Primary Purpose
PreDiabetes, Metabolic Syndrome, Overweight
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CDC's PreventT2 Program
CDC's PreventT2 Program with Added Sleep Content
Sponsored by
About this trial
This is an interventional treatment trial for PreDiabetes focused on measuring Weight loss, Women, Sleep, Intervention, Diet, Physical activity, Fitbit
Eligibility Criteria
Inclusion Criteria:
- Female (or self-identify as female)
- Age 30-70 years
- BMI 25-38 (or 23-38 if Asian or other Pacific Islander)
- Time in bed <= 7 hours on a typical weeknight
- Meets diagnostic criteria for prediabetes and/or metabolic syndrome
Exclusion Criteria:
- No regular access to telephone or email (for maintaining contact);
- No access to smartphone, tablet, or laptop computer (for using Fitbit);
- Having a condition that limits physical activity, such as brisk walking;
- Having a diagnosis of type 1 or type 2 diabetes or been previously treated with diabetes medications;
- Having a cardiac event or cardiac surgery in the past year;
- Having a metabolic condition that prevents weight loss;
- Working night shift (Midnight - 4 AM)
- Inability to complete the baseline assessment (REDCap survey and Fitbit tracking of activity, diet, and sleep for 7 days)
Sites / Locations
- University of California, San Francisco
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Active Control
Experimental
Arm Description
Participants in the active control group will receive 8 group sessions of the CDC's PreventT2 program.
Participants in the experimental group will receive 8 group sessions of the CDC's PreventT2 Program with Added Sleep Content designed to extend and improve sleep.
Outcomes
Primary Outcome Measures
Change in body mass index
Body mass index is calculated as the participant's body weight divided by the square of their height.
Secondary Outcome Measures
Change in sleep duration (objective)
Nighttime sleep duration will be objectively assessed over 7 days using a Fitbit monitor
Change in sleep quality (self-report)
Pittsburgh Sleep Quality Index (PSQI)
Change in physical activity (objective)
Daily step counts over 7 days using a Fitbit monitor
Change in physical activity (self-report)
International Physical Activity Questionnaire (IPAQ)
Change in caloric intake
Daily calories consumed over 7 days and recorded using a Fitbit monitor
Change in self-reported dietary intake
'Starting the Conversation' will be used to assess self-reported dietary intake
Change in HbA1c
HbA1c blood tests will be used to measure average blood glucose levels.
Change in Fasting Plasma Glucose (FPG)
FPG will be used to measure current blood glucose levels
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
HOMA-IR is calculated from fasting plasma glucose and insulin levels and will be used to measure insulin resistance.
Change in leptin levels
Leptin levels will be used to measure the hormone that regulates satiety
Change in lipid profile (total cholesterol, LDL, HDL, triglycerides)
A standard lipid panel will be used to measure cardiovascular risk factors
Change in blood pressure
Blood pressure will be used as a measure of cardiovascular risk
Change in waist circumference
Waist circumference will be used to measure central adiposity, an indicator of cardiovascular risk.
Change in self-assessed general health
The Promis General Health measure will be used to assess the participant's perception of their general health
Full Information
NCT ID
NCT03184337
First Posted
May 30, 2017
Last Updated
October 24, 2018
Sponsor
University of California, San Francisco
1. Study Identification
Unique Protocol Identification Number
NCT03184337
Brief Title
Women's Lifestyle Balance Study
Acronym
LB
Official Title
Women's Lifestyle and Sleep Intervention for Prediabetes and Metabolic Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
April 24, 2017 (Actual)
Primary Completion Date
December 31, 2017 (Actual)
Study Completion Date
December 31, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This pilot study aims to determine whether adding a sleep extension and sleep hygiene intervention to an existing lifestyle improvement program improves its efficacy for weight loss in those at risk for diabetes and cardiovascular disease. Half of the participants will receive the Centers for Disease Control's standard PreventT2 program and half of the participants will receive the same program with an additional sleep intervention.
Detailed Description
The goal of this pilot study is to determine whether the efficacy of an existing lifestyle improvement program can be increased by adding a sleep extension and sleep hygiene intervention. Improved sleep can improve weight loss through two possible routes: lessening fatigue may potentiate physical activity (PA), and decreasing appetite may potentiate diet improvements. A sample of 24-30 women will be assigned to either the Centers for Disease Control's (CDC's) standard PreventT2 program or the same program with an additional integrated sleep intervention. Both programs will involve 8 group sessions administered over 3 months, and all women will be followed for a total of 6 months. The primary outcome is weight loss, and secondary outcomes include sleep quality and duration, physical activity, caloric intake, and physiological indicators of cardiovascular and diabetes risk (HbA1c, HOMA-IR, lipids, blood pressure). The combined program has the potential to significantly improve weight loss in those at risk for diabetes and cardiovascular disease (CVD).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PreDiabetes, Metabolic Syndrome, Overweight
Keywords
Weight loss, Women, Sleep, Intervention, Diet, Physical activity, Fitbit
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be assigned to one of two groups.
Masking
Participant
Allocation
Non-Randomized
Enrollment
26 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active Control
Arm Type
Active Comparator
Arm Description
Participants in the active control group will receive 8 group sessions of the CDC's PreventT2 program.
Arm Title
Experimental
Arm Type
Experimental
Arm Description
Participants in the experimental group will receive 8 group sessions of the CDC's PreventT2 Program with Added Sleep Content designed to extend and improve sleep.
Intervention Type
Behavioral
Intervention Name(s)
CDC's PreventT2 Program
Intervention Description
The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.
Intervention Type
Behavioral
Intervention Name(s)
CDC's PreventT2 Program with Added Sleep Content
Intervention Description
The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
Primary Outcome Measure Information:
Title
Change in body mass index
Description
Body mass index is calculated as the participant's body weight divided by the square of their height.
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
Secondary Outcome Measure Information:
Title
Change in sleep duration (objective)
Description
Nighttime sleep duration will be objectively assessed over 7 days using a Fitbit monitor
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
Title
Change in sleep quality (self-report)
Description
Pittsburgh Sleep Quality Index (PSQI)
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
Title
Change in physical activity (objective)
Description
Daily step counts over 7 days using a Fitbit monitor
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
Title
Change in physical activity (self-report)
Description
International Physical Activity Questionnaire (IPAQ)
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
Title
Change in caloric intake
Description
Daily calories consumed over 7 days and recorded using a Fitbit monitor
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
Title
Change in self-reported dietary intake
Description
'Starting the Conversation' will be used to assess self-reported dietary intake
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
Title
Change in HbA1c
Description
HbA1c blood tests will be used to measure average blood glucose levels.
Time Frame
Baseline and 3 months, and 6 months after start of intervention
Title
Change in Fasting Plasma Glucose (FPG)
Description
FPG will be used to measure current blood glucose levels
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
Title
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Description
HOMA-IR is calculated from fasting plasma glucose and insulin levels and will be used to measure insulin resistance.
Time Frame
Baseline and 6 weeks after start of intervention
Title
Change in leptin levels
Description
Leptin levels will be used to measure the hormone that regulates satiety
Time Frame
Baseline and 6 weeks after start of intervention
Title
Change in lipid profile (total cholesterol, LDL, HDL, triglycerides)
Description
A standard lipid panel will be used to measure cardiovascular risk factors
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
Title
Change in blood pressure
Description
Blood pressure will be used as a measure of cardiovascular risk
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
Title
Change in waist circumference
Description
Waist circumference will be used to measure central adiposity, an indicator of cardiovascular risk.
Time Frame
Baseline and 6 months after start of intervention
Title
Change in self-assessed general health
Description
The Promis General Health measure will be used to assess the participant's perception of their general health
Time Frame
Baseline and 6 weeks, 3 months, and 6 months after start of intervention
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Only participant's who self-identify as women will be eligible for this pilot study. If it the results are promising, a larger trial with both genders will be pursued.
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female (or self-identify as female)
Age 30-70 years
BMI 25-38 (or 23-38 if Asian or other Pacific Islander)
Time in bed <= 7 hours on a typical weeknight
Meets diagnostic criteria for prediabetes and/or metabolic syndrome
Exclusion Criteria:
No regular access to telephone or email (for maintaining contact);
No access to smartphone, tablet, or laptop computer (for using Fitbit);
Having a condition that limits physical activity, such as brisk walking;
Having a diagnosis of type 1 or type 2 diabetes or been previously treated with diabetes medications;
Having a cardiac event or cardiac surgery in the past year;
Having a metabolic condition that prevents weight loss;
Working night shift (Midnight - 4 AM)
Inability to complete the baseline assessment (REDCap survey and Fitbit tracking of activity, diet, and sleep for 7 days)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Catherine Chesla, RN, PhD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143-0606
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
32757824
Citation
Chesla CA, Gay C, Bauer L, Bender MS, Lee K. Preventing Type 2 Diabetes Among Midlife Women: A Feasibility Study Comparing a Combined Sleep and Lifestyle Intervention With a Standard Lifestyle Intervention. Diabetes Educ. 2020 Oct;46(5):424-434. doi: 10.1177/0145721720943128. Epub 2020 Aug 6.
Results Reference
derived
Learn more about this trial
Women's Lifestyle Balance Study
We'll reach out to this number within 24 hrs